Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Antibody Fab-Fc properties outperform titer in predictive models of SIV vaccine-induced protection.

Pittala S, Bagley K, Schwartz JA, Brown EP, Weiner JA, Prado IJ, Zhang W, Xu R, Ota-Setlik A, Pal R, Shen X, Beck C, Ferrari G, Lewis GK, LaBranche CC, Montefiori DC, Tomaras GD, Alter G, Roederer M, Fouts TR, Ackerman ME, Bailey-Kellogg C.

Mol Syst Biol. 2019 May 2;15(5):e8747. doi: 10.15252/msb.20188747.

2.

An Interleukin 12 Adjuvanted Herpes Simplex Virus 2 DNA Vaccine Is More Protective Than a Glycoprotein D Subunit Vaccine in a High-Dose Murine Challenge Model.

Bagley KC, Schwartz JA, Andersen H, Eldridge JH, Xu R, Ota-Setlik A, Geltz JJ, Halford WP, Fouts TR.

Viral Immunol. 2017 Apr;30(3):178-195. doi: 10.1089/vim.2016.0136. Epub 2017 Jan 13.

PMID:
28085634
3.

Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach.

Fox CB, Orr MT, Van Hoeven N, Parker SC, Mikasa TJ, Phan T, Beebe EA, Nana GI, Joshi SW, Tomai MA, Elvecrog J, Fouts TR, Reed SG.

J Control Release. 2016 Dec 28;244(Pt A):98-107. doi: 10.1016/j.jconrel.2016.11.011. Epub 2016 Nov 12.

4.

An HIV gp120-CD4 Immunogen Does Not Elicit Autoimmune Antibody Responses in Cynomolgus Macaques.

Schwartz JA, Prado I, Misamore J, Weiss D, Francis J, Pal R, Huaman M, Cristillo A, Lewis GK, Gallo RC, DeVico AL, Fouts TR.

Clin Vaccine Immunol. 2016 Jul 5;23(7):618-27. doi: 10.1128/CVI.00115-16. Print 2016 Jul.

5.

Paring Down HIV Env: Design and Crystal Structure of a Stabilized Inner Domain of HIV-1 gp120 Displaying a Major ADCC Target of the A32 Region.

Tolbert WD, Gohain N, Veillette M, Chapleau JP, Orlandi C, Visciano ML, Ebadi M, DeVico AL, Fouts TR, Finzi A, Lewis GK, Pazgier M.

Structure. 2016 May 3;24(5):697-709. doi: 10.1016/j.str.2016.03.005. Epub 2016 Mar 31.

6.

Expression of Human Immunodeficiency Virus Type 1 Neutralizing Antibody Fragments Using Human Vaginal Lactobacillus.

Marcobal A, Liu X, Zhang W, Dimitrov AS, Jia L, Lee PP, Fouts TR, Parks TP, Lagenaur LA.

AIDS Res Hum Retroviruses. 2016 Oct/Nov;32(10-11):964-971. Epub 2016 Apr 13.

7.

Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment.

Latinovic OS, Zhang J, Tagaya Y, DeVico AL, Fouts TR, Schneider K, Lakowicz JR, Heredia A, Redfield RR.

Curr HIV Res. 2016;14(1):24-36.

PMID:
26354735
8.

NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer.

Blakely CM, Pazarentzos E, Olivas V, Asthana S, Yan JJ, Tan I, Hrustanovic G, Chan E, Lin L, Neel DS, Newton W, Bobb KL, Fouts TR, Meshulam J, Gubens MA, Jablons DM, Johnson JR, Bandyopadhyay S, Krogan NJ, Bivona TG.

Cell Rep. 2015 Apr 7;11(1):98-110. doi: 10.1016/j.celrep.2015.03.012. Epub 2015 Apr 2.

9.

Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection.

Fouts TR, Bagley K, Prado IJ, Bobb KL, Schwartz JA, Xu R, Zagursky RJ, Egan MA, Eldridge JH, LaBranche CC, Montefiori DC, Le Buanec H, Zagury D, Pal R, Pavlakis GN, Felber BK, Franchini G, Gordon S, Vaccari M, Lewis GK, DeVico AL, Gallo RC.

Proc Natl Acad Sci U S A. 2015 Mar 3;112(9):E992-9. doi: 10.1073/pnas.1423669112. Epub 2015 Feb 13. Erratum in: Proc Natl Acad Sci U S A. 2015 May 5;112(18):E2413.

10.

Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding.

Guan Y, Pazgier M, Sajadi MM, Kamin-Lewis R, Al-Darmarki S, Flinko R, Lovo E, Wu X, Robinson JE, Seaman MS, Fouts TR, Gallo RC, DeVico AL, Lewis GK.

Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):E69-78. doi: 10.1073/pnas.1217609110. Epub 2012 Dec 13.

11.

Identification and characterization of an immunogenic hybrid epitope formed by both HIV gp120 and human CD4 proteins.

Lewis GK, Fouts TR, Ibrahim S, Taylor BM, Salkar R, Guan Y, Kamin-Lewis R, Robinson JE, Devico AL.

J Virol. 2011 Dec;85(24):13097-104. doi: 10.1128/JVI.05072-11. Epub 2011 Oct 12. Erratum in: J Virol. 2012 May;86(9):5410. Robinson, James E [added].

12.

Adjuvant activity of the catalytic A1 domain of cholera toxin for retroviral antigens delivered by GeneGun.

Bagley KC, Lewis GK, Fouts TR.

Clin Vaccine Immunol. 2011 Jun;18(6):922-30. doi: 10.1128/CVI.05019-11. Epub 2011 Apr 20.

13.

Neutralization of HIV by antibodies.

Prado I, Fouts TR, Dimitrov AS.

Methods Mol Biol. 2009;525:517-31, xiv. doi: 10.1007/978-1-59745-554-1_28.

PMID:
19252841
14.

Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection.

Guan Y, Sajadi MM, Kamin-Lewis R, Fouts TR, Dimitrov A, Zhang Z, Redfield RR, DeVico AL, Gallo RC, Lewis GK.

Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3952-7. doi: 10.1073/pnas.0813392106. Epub 2009 Feb 18.

15.

Structure and function of the HIV envelope glycoprotein as entry mediator, vaccine immunogen, and target for inhibitors.

Prabakaran P, Dimitrov AS, Fouts TR, Dimitrov DS.

Adv Pharmacol. 2007;55:33-97. Review. No abstract available.

PMID:
17586312
16.

Antibody-based inhibitors of HIV infection.

Choudhry V, Zhang MY, Dimitrova D, Prabakaran P, Dimitrov AS, Fouts TR, Dimitrov DS.

Expert Opin Biol Ther. 2006 May;6(5):523-31. Review.

PMID:
16610981
17.

Progress toward the development of a bacterial vaccine vector that induces high-titer long-lived broadly neutralizing antibodies against HIV-1.

Fouts TR, DeVico AL, Onyabe DY, Shata MT, Bagley KC, Lewis GK, Hone DM.

FEMS Immunol Med Microbiol. 2003 Jul 15;37(2-3):129-34. Review.

18.
20.

Development of vaccination strategies that elicit broadly neutralizing antibodies against human immunodeficiency virus type 1 in both the mucosal and systemic immune compartments.

Hone DM, DeVico AL, Fouts TR, Onyabe DY, Agwale SM, Wambebe CO, Blattner WA, Gallo RC, Lewis GK.

J Hum Virol. 2002 Jan-Feb;5(1):17-23. Review.

PMID:
12352264
22.

Conserved structures exposed in HIV-1 envelope glycoproteins stabilized by flexible linkers as potent entry inhibitors and potential immunogens.

Chow YH, Wei OL, Phogat S, Sidorov IA, Fouts TR, Broder CC, Dimitrov DS.

Biochemistry. 2002 Jun 4;41(22):7176-82.

PMID:
12033952
23.

Development of an oral prime-boost strategy to elicit broadly neutralizing antibodies against HIV-1.

Devico AL, Fouts TR, Shata MT, Kamin-Lewis R, Lewis GK, Hone DM.

Vaccine. 2002 May 6;20(15):1968-74. Review.

PMID:
11983256
24.

Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex.

Fouts TR, Tuskan R, Godfrey K, Reitz M, Hone D, Lewis GK, DeVico AL.

J Virol. 2000 Dec;74(24):11427-36.

25.

Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infection.

Loomis-Price LD, Cox JH, Mascola JR, VanCott TC, Michael NL, Fouts TR, Redfield RR, Robb ML, Wahren B, Sheppard HW, Birx DL.

J Infect Dis. 1998 Nov;178(5):1306-16.

PMID:
9780250
27.

Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage.

Montefiori DC, Collman RG, Fouts TR, Zhou JY, Bilska M, Hoxie JA, Moore JP, Bolognesi DP.

J Virol. 1998 Mar;72(3):1886-93.

28.

An investigation of the high-avidity antibody response to glycoprotein 120 of human immunodeficiency virus type 1.

Binley JM, Arshad H, Fouts TR, Moore JP.

AIDS Res Hum Retroviruses. 1997 Aug 10;13(12):1007-15.

PMID:
9264287
30.

Optimization of live oral Salmonella-HIV-1 vaccine vectors for the induction of HIV-specific mucosal and systemic immune responses.

Hone DM, Wu S, Powell RJ, Pascual DW, Van Cott J, McGhee J, Fouts TR, Tuskan RG, Lewis GK.

J Biotechnol. 1996 Jan 26;44(1-3):203-7. Review.

PMID:
8717405
31.

Construction and immunogenicity of Salmonella typhimurium vaccine vectors that express HIV-1 gp120.

Fouts TR, Tuskan RG, Chada S, Hone DM, Lewis GK.

Vaccine. 1995 Dec;13(17):1697-705.

PMID:
8719522
32.
33.

Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans.

Gonzalez C, Hone D, Noriega FR, Tacket CO, Davis JR, Losonsky G, Nataro JP, Hoffman S, Malik A, Nardin E, Sztein MB, Heppner DG, Fouts TR, Isibasi A, Levine MM, et al.

J Infect Dis. 1994 Apr;169(4):927-31.

PMID:
8133113
34.

Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies.

Abacioglu YH, Fouts TR, Laman JD, Claassen E, Pincus SH, Moore JP, Roby CA, Kamin-Lewis R, Lewis GK.

AIDS Res Hum Retroviruses. 1994 Apr;10(4):371-81.

PMID:
8068416
35.

Expression of human immunodeficiency virus antigens in an attenuated Salmonella typhi vector vaccine.

Hone DM, Lewis GK, Beier M, Harris A, McDaniels T, Fouts TR.

Dev Biol Stand. 1994;82:159-62. Review.

PMID:
7958470

Supplemental Content

Loading ...
Support Center